These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37996194)

  • 1. Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial.
    Vural Keskinler M; Telci Caklili O; Oguz A
    Lancet Diabetes Endocrinol; 2023 Dec; 11(12):894. PubMed ID: 37996194
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial.
    Ahmed A; Anker SD; Butler J; Bakris GL; Bhatt DL; Fonarow GC; Packer M
    Lancet Diabetes Endocrinol; 2023 Dec; 11(12):892-894. PubMed ID: 37996192
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial.
    Ceriello A; Prattichizzo F; Berra CC; Caballero AE
    Lancet Diabetes Endocrinol; 2023 Dec; 11(12):894-895. PubMed ID: 37996193
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial - Authors' reply.
    Xie Y; Al-Aly Z
    Lancet Diabetes Endocrinol; 2023 Dec; 11(12):895-896. PubMed ID: 37996195
    [No Abstract]   [Full Text] [Related]  

  • 5. Intensive glucose lowering arm of diabetes trial is stopped after excess deaths.
    Mayor S
    BMJ; 2008 Feb; 336(7641):407. PubMed ID: 18292149
    [No Abstract]   [Full Text] [Related]  

  • 6. Use of Real-World Data to Emulate a Clinical Trial and Support Regulatory Decision Making: Assessing the Impact of Temporality, Comparator Choice, and Method of Adjustment.
    Abrahami D; Pradhan R; Yin H; Honig P; Baumfeld Andre E; Azoulay L
    Clin Pharmacol Ther; 2021 Feb; 109(2):452-461. PubMed ID: 32767673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C; Jun M; Badve SV; Pilmore H; White SL; Hawley C; Cass A; Perkovic V; Zoungas S
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD009966. PubMed ID: 28238223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
    Tandon N; Ali MK; Narayan KM
    Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liraglutide for the treatment of type 2 diabetes.
    Shyangdan D; Cummins E; Royle P; Waugh N
    Health Technol Assess; 2011 May; 15 Suppl 1():77-86. PubMed ID: 21609656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of glucose-lowering on outcome incidence in diabetes mellitus and the modulating role of blood pressure and other clinical variables: overview, meta-analysis of randomized trials.
    Thomopoulos C; Bazoukis G; Ilias I; Tsioufis C; Makris T
    J Hypertens; 2019 Oct; 37(10):1939-1949. PubMed ID: 31157748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Safety and Effectiveness of Canagliflozin Treatment for Type 2 Diabetes Mellitus in Japan: SAPPHIRE, a Long-Term, Large-Scale Post-Marketing Surveillance.
    Inagaki N; Nangaku M; Sakata Y; Sasaki K; Mori-Anai K; Iwasaki T; Hamada K
    Adv Ther; 2022 Jan; 39(1):674-691. PubMed ID: 34853985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is it possible to reduce cardiovascular risk with glucose-lowering approaches?
    Gerstein HC
    Nat Rev Endocrinol; 2009 May; 5(5):270-5. PubMed ID: 19444260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucose-lowering therapies and cancer risk: the trials and tribulations of trials and observations.
    Johnson JA; Yasui Y
    Diabetologia; 2010 Sep; 53(9):1823-6. PubMed ID: 20523967
    [No Abstract]   [Full Text] [Related]  

  • 17. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitors of type 2 sodium glucose co-transporters--a new strategy for diabetes treatment.
    Bołdys A; Okopień B
    Pharmacol Rep; 2009; 61(5):778-84. PubMed ID: 19904000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of type 2 diabetes: future approaches.
    Bailey CJ; Day C
    Br Med Bull; 2018 Jun; 126(1):123-137. PubMed ID: 29897499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of type 2 diabetes: inadequate assessment of oral antidiabetic combinations.
    Prescrire Int; 2003 Feb; 12(63):28-30. PubMed ID: 12602406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.